Market Place
Sourcing Support
Domain Strengthens IP For Its Treg Depleting anti-CCR8 Antibodies Series
06 Jun 2024 //
BUSINESSWIRE
Domain to Participate at Premier Investor and Healthcare Conferences
08 Apr 2024 //
BUSINESSWIRE
Domain to Present Latest Data on DT-9045 at AACR 2024 Annual Meeting
26 Mar 2024 //
BUSINESSWIRE
Domain And Chime Partner To Manufacture Anti-CCR8 Antibody For Cancer
12 Mar 2024 //
PRESS RELEASE
Domain Therapeutics and Chime Biologics announce manufacturing agreement
12 Mar 2024 //
PR NEWSWIRE
Domain Therapeutics Further Strengthens Leadership Team
08 Feb 2024 //
BUSINESSWIRE
Domain Therapeutics Awarded Hospital-University RHU SPRINT Consortium Grant
25 Jan 2024 //
BUSINESSWIRE
Domain Therapeutics Strengthens Leadership Team
08 Jan 2024 //
BUSINESSWIRE
Domain announces nomination of best-in-class CCR8 antibody candidate, DT-701
29 Jun 2023 //
GLOBENEWSWIRE
Domain Therapeutics announces first patient dosed with DT-9081 in phase I study
05 Jan 2023 //
GLOBENEWSWIRE
Domain strengthens Scientific Advisory Board immuno-oncology experts
08 Dec 2022 //
GLOBENEWSWIRE
Domain presents new data on its EP4R and CCR8 antagonists at 2022 SITC
10 Nov 2022 //
GLOBENEWSWIRE
Domain to progress into clinical trials with its EP4R antagonist DT-9081
19 Oct 2022 //
GLOBENEWSWIRE
Domain Therapeutics to present new data on its EP4R and CCR8 antagonists at 2022
05 Oct 2022 //
GLOBENEWSWIRE
Domain Tx Receives Development Milestone Payment from Merck for M1069
28 Jun 2022 //
BUSINESSWIRE
Domain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific Officer
13 Jun 2022 //
BUSINESSWIRE
Domain Therapeutics Raises $42m Series A Financing
10 May 2022 //
BUSINESSWIRE
Domain Therapeutics and Explicyte enter immuno-oncology partnership
10 Mar 2022 //
PHARMAFILE
Sale of Bionomics’ French Subsidiaries to Domain Therapeutics
11 Dec 2019 //
BIOSPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.